Abstract

Studies focused on development of an attenuated vaccine against Mycobacterium avium subsp. paratuberculosis (Map), the causative agent of paratuberculosis (Ptb) in cattle and other species, revealed that deletion of relA, a global gene regulator, abrogates the ability of Map to establish a persistent infection. In the absence of relA, cattle develop CD8 cytotoxic T cells (CTL) with the ability to kill intracellular bacteria. Analysis of the recall response to a relA mutant, Map/ΔrelA, with cells from a vaccinated steer demonstrated that a 35-kDa membrane peptide (MMP) is one of the targets of the response. This observation suggested that it might be possible to develop a peptide-based vaccine. As reported here, the gene encoding the hypothetical MMP ORF, MAP2121c, was modified for expression in mammalian cells as a first step in developing an expression cassette for incorporation into a mammalian expression vector. The modified sequence of MMP, tPA-MMP, was mutated to generate two additional sequences for the study, one with substitutions to replace five potential residues that could be glycosylated, tPA-MMP-5mut, and one with substitutions to replace the first two potential residues that could be glycosylated, tPA-MMP-2mut. The sequences were placed in an expression cassette to produce peptides for analysis. An ex vivo platform was used with flow cytometry and a bacterium viability assay to determine if modifications in the gene encoding MMP for expression in mammalian cells altered its capacity to elicit development of CD8 CTL, essential for its use in a peptide-based vaccine. Monocyte-depleted PBMC (mdPBMC) were stimulated with antigen-presenting cells (APC) pulsed with different MMP constructs. CD4 and CD8 T cells proliferated in response to stimulation with MMP (control) expressed in Escherichia coli (eMMP), tPA-MMP, and tPA-MMP-2mut. CD8 T cells retained the capacity to kill intracellular bacteria. The tPA-MMP-5mut failed to elicit a proliferative response and was not included in further studies. The data show that the expression cassettes containing MMP and MMP-2mut can be used to screen and select a mammalian expression vector for the development of an efficacious peptide-based vaccine against Ptb.

Highlights

  • Mycobacterium avium subsp. paratuberculosis (Map) is a mycobacterial pathogen with a broad host range that includes livestock, humans, and wildlife [1,2,3,4,5]

  • Efforts to develop vaccines against mycobacterial pathogens have been impeded by the lack of understanding the mechanisms used by the pathogens to establish a persistent infection

  • The immune response that develops against Mycobacterium tuberculosis (Mtb) is sufficient to maintain immune control for a lifetime in most exposed subjects

Read more

Summary

Introduction

Mycobacterium avium subsp. paratuberculosis (Map) is a mycobacterial pathogen with a broad host range that includes livestock, humans, and wildlife [1,2,3,4,5]. Paratuberculosis (Map) is a mycobacterial pathogen with a broad host range that includes livestock, humans, and wildlife [1,2,3,4,5]. It is the causative agent of paratuberculosis (Ptb) in livestock. Similar to other pathogenic mycobacteria, initial infection leads to development of a persistent infection under immune control. Attempts to clear Map from livestock herds using management strategies and improved early diagnostic methods has not been successful [6,7,8,9,10]. Development of a Map livestock vaccine is urgently needed

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.